Boiron S.A.

Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
  • TickerBOI
  • ISINFR0000061129
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/10/2019

...

Christophe-Raphaël Ganet

Boiron : More uncertainty?

>Performance lagged in H1 in France and internationally - From our road show with the group, we note:1/ interim earnings (underlying operating profit: € 6m est. vs € 35.4m in H1 2018) were impacted by i/ the decline in business (-8.5%) notably due to an unfavourable comparison base in the US (lack of a winter pathology), attacks against homoeopathic medicine in a number of countries (France, Spain, Belgium, Italy) and a “generational effect” in France (the retire...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/09/2019

...

Christophe-Raphaël Ganet

Boiron : Encore de l’incertitude ?

>La France, comme l’international, était à la traine au S1 - De notre roadshow avec la société, nous retenons surtout que : 1/ les résultats semestriels (ROC : 6 M€ vs 35,4 M€ au S1 2018) ont été impactés par i/ la baisse de l’activité (-8,5%) imputable en particulier, à un effet de base négatif aux USA (absence de pathologie), des attaques contre l’homéopathie dans plusieurs pays (France, Espagne, Belgique, Italie) et un « effet générationnelle » en France (départs à...

Ahmed Ben Salem ...
  • Alain William
  • Antoine Boivin-Champeaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Ayachi
  • François Maury
  • Geoffroy Michalet
  • Georges Dieng
  • Hana Maalej
  • Jean-François Granjon
  • Jerôme Bodin
  • Nicolas David
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/05/2019

...

Christophe-Raphaël Ganet

Boiron : More uncertainty?

>Performance lagged in H1 in France and internationally - From our road show with the group, we note:1/ interim earnings (underlying operating profit: € 6m est. vs € 35.4m in H1 2018) were impacted by i/ the decline in business (-8.5%) notably due to an unfavourable comparison base in the US (lack of a winter pathology), attacks against homoeopathic medicine in a number of countries (France, Spain, Belgium, Italy) and a “generational effect” in France (the retire...

Christophe-Raphaël Ganet

Boiron : Encore de l’incertitude ?

>La France, comme l’international, était à la traine au S1 - De notre roadshow avec la société, nous retenons surtout que : 1/ les résultats semestriels (ROC : 6 M€ vs 35,4 M€ au S1 2018) ont été impactés par i/ la baisse de l’activité (-8,5%) imputable en particulier, à un effet de base négatif aux USA (absence de pathologie), des attaques contre l’homéopathie dans plusieurs pays (France, Espagne, Belgique, Italie) et un « effet générationnelle » en France (départs à...

Ahmed Ben Salem ...
  • Alain William
  • Antoine Boivin-Champeaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Ayachi
  • François Maury
  • Geoffroy Michalet
  • Georges Dieng
  • Hana Maalej
  • Jean-François Granjon
  • Jerôme Bodin
  • Nicolas David
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/05/2019

...

Christophe-Raphaël Ganet

Boiron : Slump in H1 2019 operating profit – lower forecasts – still too much stress

>H1 2019 operating profit (-83%) well short of expectations: fall in sales and one-offs - H1 2019 operating profit slumped to € 6m from € 35.4m in H1 2018.The press release also indicated that one-off items generated an unfavourable change in ‘other operating income and expenses’ of € 11m, whereas in H1 2018 a capital gain of € 6.2m had been booked on the sale of the Levallois-Perret facility. In H1 2019, asset impairments and provisions were booked in Belgium, t...

Ahmed Ben Salem ...
  • Alain William
  • Antoine Boivin-Champeaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Fatma Ayachi
  • François Maury
  • Geoffroy Michalet
  • Georges Dieng
  • Hana Maalej
  • Jean-François Granjon
  • Jerôme Bodin
  • Nicolas David
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 05/09/2019

...

1 director bought

A director at Boiron bought 441 shares at 68.800EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/10/2019

...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/09/2019

...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 06/28/2019

We are initiating coverage of SMCP, one of the world leaders in accessible luxury with a Buy recommendation and a target price of € 20.5. The group is known for delivering steady growth in each of its three brands. Taking the best of both worlds, it combines the benefits of luxury and fast fashion. We see the current valuation as an investment opportunity (EV/EBITDA 2019 of 6.3x, 30% discount vs. peers) in light of the group’s solid financial profile and significant growth potential, ...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 28/06/2019

Nous initions la couverture de SMCP, un des leaders mondiaux du luxe abordable avec une recommandation Achat et un OC de 20.5 €. Le groupe se caractérise par une croissance pérenne sur chacune de ses trois marques en prenant le meilleur de deux mondes, le Luxe et la Fast-fashion. La valorisation actuelle nous semble être une opportunité (6.3x VE/EBITDA 2019e, décote de 30% vs pairs) sur ce dossier dont le profil financier est de qualité et le potentiel de croissance important, en part...

Christophe-Raphaël Ganet ...
  • Emmanuel Matot
  • Laurence Hofmann

ODDO BHF Small & MIDCAP MORNING NEWS - 05/20/2019

...

Increased risk weighs on BOIRON SA, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of BOIRON SA (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 21, 2019, the closing price was EUR 37.35 and its target price was estimated at EUR 35.48.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Florian Béchaz

Boiron - Assemblée Générale des actionnaires du 16 mai 2019

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 7,69% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Jehanne Leroy

Proxy Report - 17/05/2018

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 8,33% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Boiron 2014

​Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Matthieu DRIOL

Short term view - BOIRON SA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Medium term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €41.74. Passing €88.94 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch